Patents by Inventor Hans-Christian PHILIPP

Hans-Christian PHILIPP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11999766
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: June 4, 2024
    Assignee: Boehringer Ingelheim Vetmedia GmbH
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11964999
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: April 23, 2024
    Assignee: Boehringer Ingelheim Vetmedia GmbH
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230340028
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: November 28, 2022
    Publication date: October 26, 2023
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
  • Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein
    Patent number: 11744888
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: September 5, 2023
    Inventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
  • H52 IBV vaccine with heterologous spike protein
    Patent number: 11696947
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: July 11, 2023
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Egbert Siegfried Mundt, Hans-Christian Philipp
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11512115
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • Method of Treating or Preventing Clinical Signs Caused by Infectious Bronchitis Virus with 4/91 IBV Vaccine having Heterologous Spike Protein
    Publication number: 20220265815
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: December 8, 2021
    Publication date: August 25, 2022
    Inventors: Annika KRAEMER-KUEHL, Hans-Christian PHILIPP
  • 4/91 IBV vaccine with heterologous spike protein
    Patent number: 11224649
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: January 18, 2022
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
  • MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20200354410
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 12, 2020
    Inventors: Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
  • H52 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
    Publication number: 20200129614
    Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Annika KRAEMER-KUEHL, Egbert Siegfried MUNDT, Hans-Christian PHILIPP
  • 4/91 IBV VACCINE WITH HETEROLOGOUS SPIKE PROTEIN
    Publication number: 20200129613
    Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 30, 2020
    Inventors: Annika KRAEMER-KUEHL, Hans-Christian PHILIPP